Hiseco: Obtained the Drug Registration Certificate for the Class 1 Innovative Drug Enricofen Injection

2025-05-21 12:00:15

Hiseco announced that on May 21, the company received the "Drug Registration Certificate" for the Class 1 innovative drug Anrekofen Injection (trade name: Sishujing®, research and development code: HSK21542) issued by the National Medical Products Administration. Anrekofen Injection is a highly selective peripheral kappa opioid receptor (κOpioid Receptor, KOR) agonist independently developed by the company. It is also the world's first white-prescription opioid analgesic drug that has obtained analgesic indications and does not need to be included in the management of narcotic drugs. It has important clinical and social significance.

Cisco

Email Subscription

Newsletters and emails are now available! Delivered on time, every weekday, to keep you up to date with North American business news.

Weekly Highlights

                                    Amazon will soon begin directly sourcing a wider variety of Nike products to expand selection for customers in the United States.
                            2025-05-22

                                    U.S. stocks closed, Dow fell 0.27%
                            2025-05-21

                                    Red Hat announces Red Hat AI Inference Server
                            2025-05-21

                                    Zheng Zhajie, Director of the National Development and Reform Commission, meets with Luhut, Chairman of the Indonesian National Economic Council
                            2025-05-21

                                    China Electronics Port stated on an interactive platform on May 22 that the company's current business cooperation with Xiaomi is mainly in mobile phones, home appliances, televisions, automobiles, ecological chains, etc., and there is no business cooperation in self-developed chips.
                            2025-05-22